← Oncology Approval Tracker

FDA DECISION ·

Bortezomib for Injection

bortezomib · Fresenius Kabi

FDA approvalNew dosing regimenMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds a retreatment dosing regimen for multiple myeloma in the injectable bortezomib label.

LAMPGEN ANALYSIS

Why it matters

The supplement adds a dosing pathway for reusing bortezomib after a prior course.

What research teams should watch

Document prior response and the interval since treatment, and verify the retreatment schedule and last tolerated dose.

PRIMARY RECORDS

Sources